|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Elixir Pharmaceuticals Establishes National Diabetes Advisory Board
4/9/2008 9:08:32 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Elixir Pharmaceuticals, Inc., announced today the formation of its U.S. Diabetes Advisory Board to provide independent scientific and clinical advice regarding the Company's product candidates in phase III development, Glinsuna™ (mitiglinide) and Metgluna™ (mitiglinide plus metformin), for the treatment of type 2 diabetes, as well as to provide input on other Elixir product candidates in development to treat metabolic diseases. James R. Gavin III, M.D., Ph.D., Clinical Professor of Medicine at Emory University and past president of the American Diabetes Association (ADA), has been named chair of the Elixir Diabetes Advisory Board. Members of the advisory board also include: Lawrence Blonde, M.D., Rhoda H. Cobin, M.D., John E. Gerich, M.D., Paul S. Jellinger, M.D., John L. Leahy, M.D. and Janet B. McGill, M.D.
|
|
|
|
|
|
|
|
|
|
|